Breaking News, Collaborations & Alliances

Pregene Partners with CellPoint to Develop Anti-BCMA CAR-T Cell Therapy

The potential of the therapy to treat patients with relapsed/refractory multiple myeloma has been validated in clinical trials.

Author Image

By: Charlie Sternberg

Associate Editor

Shenzhen Pregene Biopharma, a clinical-stage biopharmaceutical company, and CellPoint, a cell therapy company developing CAR-T therapeutics for use at the point-of-care (POC), have entered an exclusive license agreement for the development and commercialization of PRG-1801, Pregene’s single domain antibody-based anti-BCMA chimeric antigen receptor T cell (CAR-T) program, for the treatment of hematological indications in Europe and the United States.   PRG-1801 is a single domain antibody...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters